AQR Capital Management
KZR

AQR Capital Management’s Kezar Life Sciences KZR Stock Holding History

AQR Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,144
Closed -$19.3K – 2642
2024
Q1 		$19.3K Buy
+2,144
New +$19.5K ﹤0.01% 2393
2023
Q3 		– Sell
-1,699
Closed -$41.6K – 2347
2023
Q2 		$41.6K Buy
+1,699
New +$44.2K ﹤0.01% 2168
2023
Q1 		– Sell
-1,485
Closed -$105K – 2216
2022
Q4 		$105K Sell
1,485
-102
-6% -$7.56K ﹤0.01% 2140
2022
Q3 		$137K Sell
1,587
-2,240
-59% -$218K ﹤0.01% 2086
2022
Q2 		$317K Buy
3,827
+2,333
+156% +$206K ﹤0.01% 1848
2022
Q1 		$248K Buy
1,494
+468
+46% +$67.2K ﹤0.01% 2011
2021
Q4 		$172K Buy
+1,026
New +$116K ﹤0.01% 2107
2021
Q1 		– Sell
-2,477
Closed -$129K – 2233
2020
Q4 		$129K Buy
+2,477
New +$138K ﹤0.01% 2136

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

AQR Capital Management's KZR Position: Q2 2024 in Review

AQR Capital Management sold out of Kezar Life Sciences (KZR) in Q2 2024, closing a stake of 2,144 shares — an estimated $19.3K sold.

AQR Capital Management first reported a position in KZR in Q4 2020 and held it in 8 quarters. The position peaked at $317K in Q2 2022. 81 funds tracked by Wall St. Rank hold KZR as of Q2 2024.

  • AQR Capital Management reported no remaining Kezar Life Sciences position as of Q2 2024 after selling out during the quarter.
  • AQR Capital Management sold 2,144 Kezar Life Sciences shares in Q2 2024, an estimated $19.3K.
  • AQR Capital Management first reported a position in Kezar Life Sciences in Q4 2020 and held it in 8 quarters.
  • AQR Capital Management's Kezar Life Sciences position peaked at $317K in Q2 2022.
  • 81 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2024.

Based on AQR Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.